Company intelligence / Profile preview

Ellex

Adelaide, South Australia, Australia

Ownership: Private
Employees: ~175
Development stage: Other

Overview

Ellex's flagship 2RT™ technology has shown efficacy in clinical trials for early Age-related Macular Degeneration and Diabetic Retinopathy, demonstrating improvement in visual function and reduction of disease-associated deposits without retinal thermal damage[3][8]. The iTrack™ minimally invasive glaucoma device yields superior intraocular pressure reduction compared to competitors, supporting its commercial growth[5].

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Previously Alcon (OEM)CoherentLumenis (OEM)[1]

Beyond the preview

Go deeper on Ellex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ellex.

Explore the full profile